Soricimed has developed a novel platform consisting of a number of proprietary peptides that target a specific calcium ion channel, TRPV6. Our novel peptides target and bind to TRPV6, resulting in the ability to act as a primary targeted therapeutic or as delivery ligands for other anti-cancer payloads. When used as a delivery ligand, our targeting peptides can deliver other anti-cancer agents directly and rapidly to the cancer cells. This method of delivery can:
Applications of our platform currently include Radioligand Therapies that provide precise delivery of a therapeutic radioisotope directly to tumors, and Peptide-Drug Conjugates (PDC’s) that deliver potent cancer-killing payloads directly to tumors.
Soricimed’s targeting ligands are proprietary synthetic peptides. These peptide ligands bind to TRPV6 – a calcium ion channel that is overexpressed in cancer cells. Cancers where TRVP6 becomes over-expressed include prostate, pancreatic, ovarian, breast, uterine, colon, and certain other solid tumor cancers.
Illustration of an enlarged prostate with cancerous cells growing.
Prostate cancer is one of many solid tumour cancers where TRVP6 becomes over-expressed.
| 
| 
| 